TOP TEN perturbations for 40030_at (Homo sapiens)

Organism: Homo sapiens
Gene: 40030_at
Selected probe(set): 206279_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 40030_at (206279_at) across 6674 perturbations tested by GENEVESTIGATOR:

atopic dermatitis study 20 (lesional; placebo; baseline) / normal skin tissue

Relative Expression (log2-ratio):-3.278595
Number of Samples:6 / 2
Experimental atopic dermatitis study 20 (lesional; placebo; baseline)
Lesional skin biopsies isolated from patients with atopic dermatitis before placebo treatment (at baseline). Adult patients (both males and females; ≥18 years of age) with moderate to severe AD (documented for ≥ 12 months) were enrolled into study. Patients met Hanifin and Rajka criteria for AD at screening. They had AD that was not adequately controlled by a stable regimen (≥4 weeks) of topical corticosteroids or topical calcineurin inhibitors within 6 months of screening, or was considered inappropriate for topical therapy because of side effects or safety risks. Further patients' characteristics: AD-affected body surface area >10%, EASI score >12, and sPGA-A score >3. Patients were stratified by geographic region (North America and Japan) and within region. Exclusion criteria: a) significant or major uncontrolled disease; b) active or history of incompletely treated tuberculosis; c) history of malignancy within the past 5 years (except treated/cured squamous cell or basal cell in situ carcinomas or cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within 5 years prior to screening); d) unstable asthma; e) significant infection within 2 weeks of screening; f) active skin infection; g) use of phototherapy or systemic immunosuppressive drugs within 4 weeks; h) use of interferon-gama within 12 weeks; i) use of biologics within 12 to 24 weeks of baseline.
Control normal skin tissue
Skin tissue biopsies obtained from control subjects.

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):-2.9020252
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

atopic dermatitis study 20 (lesional; apremilast; 40mg; baseline) / atopic dermatitis study 20 (lesional; placebo; baseline)

Relative Expression (log2-ratio):2.642602
Number of Samples:7 / 6
Experimental atopic dermatitis study 20 (lesional; apremilast; 40mg; baseline)
Lesional skin biopsies isolated from patients with atopic dermatitis before treatment with 40 mg of apremilast (at baseline). Adult patients (both males and females; ≥18 years of age) with moderate to severe AD (documented for ≥ 12 months) were enrolled into study. Patients met Hanifin and Rajka criteria for AD at screening. They had AD that was not adequately controlled by a stable regimen (≥4 weeks) of topical corticosteroids or topical calcineurin inhibitors within 6 months of screening, or was considered inappropriate for topical therapy because of side effects or safety risks. Further patients' characteristics: AD-affected body surface area >10%, EASI score >12, and sPGA-A score >3. Patients were stratified by geographic region (North America and Japan) and within region. Exclusion criteria: a) significant or major uncontrolled disease; b) active or history of incompletely treated tuberculosis; c) history of malignancy within the past 5 years (except treated/cured squamous cell or basal cell in situ carcinomas or cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within 5 years prior to screening); d) unstable asthma; e) significant infection within 2 weeks of screening; f) active skin infection; g) use of phototherapy or systemic immunosuppressive drugs within 4 weeks; h) use of interferon-gama within 12 weeks; i) and use of biologics within 12 to 24 weeks of baseline.
Control atopic dermatitis study 20 (lesional; placebo; baseline)
Lesional skin biopsies isolated from patients with atopic dermatitis before placebo treatment (at baseline). Adult patients (both males and females; ≥18 years of age) with moderate to severe AD (documented for ≥ 12 months) were enrolled into study. Patients met Hanifin and Rajka criteria for AD at screening. They had AD that was not adequately controlled by a stable regimen (≥4 weeks) of topical corticosteroids or topical calcineurin inhibitors within 6 months of screening, or was considered inappropriate for topical therapy because of side effects or safety risks. Further patients' characteristics: AD-affected body surface area >10%, EASI score >12, and sPGA-A score >3. Patients were stratified by geographic region (North America and Japan) and within region. Exclusion criteria: a) significant or major uncontrolled disease; b) active or history of incompletely treated tuberculosis; c) history of malignancy within the past 5 years (except treated/cured squamous cell or basal cell in situ carcinomas or cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within 5 years prior to screening); d) unstable asthma; e) significant infection within 2 weeks of screening; f) active skin infection; g) use of phototherapy or systemic immunosuppressive drugs within 4 weeks; h) use of interferon-gama within 12 weeks; i) use of biologics within 12 to 24 weeks of baseline.

atopic dermatitis study 20 (lesional; apremilast; 30mg; 12wk) / atopic dermatitis study 20 (lesional; placebo; 12wk)

Relative Expression (log2-ratio):2.5561256
Number of Samples:4 / 5
Experimental atopic dermatitis study 20 (lesional; apremilast; 30mg; 12wk)
Lesional skin biopsies isolated from patients with atopic dermatitis treated with 30 mg of apremilast for 12 weeks (twice daily). Adult patients (both males and females; ≥18 years of age) with moderate to severe AD (documented for ≥ 12 months) were enrolled into study. Patients met Hanifin and Rajka criteria for AD at screening. They had AD that was not adequately controlled by a stable regimen (≥4 weeks) of topical corticosteroids or topical calcineurin inhibitors within 6 months of screening, or was considered inappropriate for topical therapy because of side effects or safety risks. Further patients' characteristics: AD-affected body surface area >10%, EASI score >12, and sPGA-A score >3. Patients were stratified by geographic region (North America and Japan) and within region. Exclusion criteria: a) significant or major uncontrolled disease; b) active or history of incompletely treated tuberculosis; c) history of malignancy within the past 5 years (except treated/cured squamous cell or basal cell in situ carcinomas or cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within 5 years prior to screening); d) unstable asthma; e) significant infection within 2 weeks of screening; f) active skin infection; g) use of phototherapy or systemic immunosuppressive drugs within 4 weeks; h) use of interferon-gama within 12 weeks; i) use of biologics within 12 to 24 weeks of baseline. ATC code:
Control atopic dermatitis study 20 (lesional; placebo; 12wk)
Lesional skin biopsies isolated from patients with atopic dermatitis treated with placebo for 12 weeks. Adult patients (both males and females; ≥18 years of age) with moderate to severe AD (documented for ≥ 12 months) were enrolled into study. Patients met Hanifin and Rajka criteria for AD at screening. They had AD that was not adequately controlled by a stable regimen (≥4 weeks) of topical corticosteroids or topical calcineurin inhibitors within 6 months of screening, or was considered inappropriate for topical therapy because of side effects or safety risks. Further patients' characteristics: AD-affected body surface area >10%, EASI score >12, and sPGA-A score >3. Patients were stratified by geographic region (North America and Japan) and within region. Exclusion criteria: a) significant or major uncontrolled disease; b) active or history of incompletely treated tuberculosis; c) history of malignancy within the past 5 years (except treated/cured squamous cell or basal cell in situ carcinomas or cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within 5 years prior to screening); d) unstable asthma; e) significant infection within 2 weeks of screening; f) active skin infection; g) use of phototherapy or systemic immunosuppressive drugs within 4 weeks; h) use of interferon-gama within 12 weeks; i) use of biologics within 12 to 24 weeks of baseline.

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-2.4473057
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

juvenile enthesitis related arthritis study 1 (ERA) / polyarticular JIA study 3 (RF positive)

Relative Expression (log2-ratio):2.392641
Number of Samples:26 / 15
Experimental juvenile enthesitis related arthritis study 1 (ERA)
Peripheral blood mononuclear cell (PBMC) samples from children with enthesitis related arthritis (ERA). All patients were free of disease modifying antirheumatic drugs.
Control polyarticular JIA study 3 (RF positive)
Peripheral blood mononuclear cell (PBMC) samples from children with rheumatoid factor negative (RFpos) polyarticular juvenile rheumatoid arthritis. All patients were free of disease modifying antirheumatic drugs.

ixekizumab study 2 / normal blood sample

Relative Expression (log2-ratio):2.250183
Number of Samples:7 / 30
Experimental ixekizumab study 2
Whole blood samples from patients with psoriasis. Sample was taken at week 2 after application of 150mg ixekizumab. Ixekizumab is a putative anti-IL-17mAb. ATC code:---
Control normal blood sample
Whole blood samples of healthy volunteers.

NCI-H358 / HCC827

Relative Expression (log2-ratio):2.2391233
Number of Samples:6 / 6
Experimental NCI-H358
Human bronchioloalveolar carcinoma derived cell line. Synonyms:H358; H-358 Cellosaurus code:
Control HCC827
Human primary cancer cell line derived from the lung of a patient with non-small-cell lung cancer. Synonyms:HCC-827; HCC0827 Cellosaurus code:

CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)

Relative Expression (log2-ratio):2.1810179
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-28t28Z; post-infusion)
CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):2.1124601
Number of Samples:2 / 3
Experimental glioma study 17 (small cell glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.